As a physician who prescribes GLP-1 medications like Ozempic, Wegovy, semaglutide, and tirzepatide, I explain why increasing ...

Hims & Hers and Novo Nordisk’s very public eight-month-long feud over GLP-1 drugs just came to an end. Today, the two former rivals officially announced that they’re putting down their dukes and ...

Health news and commentary gathered by MedPage Today staff ...

GLP-1 agonist market expected to grow from $70B in 2025 to $201B in 20301Proprietary Forzet formulation provides ...

A peer-reviewed study of more than 46,000 older adults with type 2 diabetes found that patients who started GLP-1 receptor agonist drugs faced an 11 percent higher risk of fragility fractures compared ...

Hers is currently offering 20% off GLP-1 medication for eligible subscribers who pay over $500 for weight-loss services.

New research suggests GLP-1 drugs may increase the risk of bone and tendon injuries and other conditions, including ...

The FDA has issued warnings to 30 telehealth companies for making false or misleading claims regarding compounded GLP-1 ...

Al-Aly and his colleagues found that people starting the GLP-1 drugs had lower risks of developing addiction to multiple ...

The companies have been embroiled in a row about compounded GLP-1 drugs that escalated to a lawsuit last month. The legal action has now been dropped and the former adversaries have struck a deal that ...

Diabetes and obesity drugs also lead to large reductions in adverse cardiovascular events, and the benefits aren’t just down ...

The effect was seen across a wide variety of addictive and habit-forming substances, including cocaine, opioids, alcohol, ...